Your browser doesn't support javascript.
loading
The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis.
Heller, S; Bowering, K; Raskin, P; Liebl, A; Buchholtz, K; Gorst-Rasmussen, A; Pieber, T R.
Afiliação
  • Heller S; Academic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.
  • Bowering K; Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Raskin P; University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Liebl A; Center for Diabetes and Metabolism, m&i-Fachklinik Bad Heilbrunn, Bad Heilbrunn, Germany.
  • Buchholtz K; Novo Nordisk A/S, Søborg, Denmark.
  • Gorst-Rasmussen A; Novo Nordisk A/S, Søborg, Denmark.
  • Pieber TR; Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
Diabet Med ; 2018 May 26.
Article em En | MEDLINE | ID: mdl-29802636
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2018 Tipo de documento: Article